Analyst Profile

Followed by 375 followers
.
Brian Abrahams

Brian Abrahams

RBC Capital
Wall Street Analyst
#808 out of 8,142 Wall Street Analysts
#1,757 out of 24,385 experts

Success Rate

53%
197 out of 370 transactions made a profit

Average Return

+7.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Brian Abrahams's trades since 2009 and holding each position for 1 Year would result in 53.24% of your transactions generating a profit, with an average return of 7.2% per rating.

Stock Rating Distribution

2KRatings
61.51% Buy
38.17% Hold
0.32% Sell
Distribution of Brian Abrahams's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
CanadaCanadian Market
United KingdomUK Market

Best Rating

Stock:
Pliant Therapeutics, Inc.
(PLRX)
Rating:Buy
Date:May 10, 2022 - Today
Return:+293.50%
The most profitable rating made by Brian Abrahams

Brian Abrahams's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
~RPRX
Repros
Jul 01, 2009
Hold
Downgraded
1Ratings
0.00%
Novavax
Sep 02, 2009
Hold
Downgraded
1Ratings
0.00%
GENZ
Genzyme
Sep 21, 2009
Hold
Downgraded
2Ratings
0.00%
ANDS
Anadys Pharm
Feb 25, 2010
Hold
Downgraded
1Ratings
0.00%
IDIX
Idenix Pharma
Jun 11, 2010
Buy
Upgraded
1Ratings
0.00%
Protalix Biotherapeutics
Jun 25, 2012
Hold
Downgraded
1Ratings
0.00%
XNPT
XenoPort
Oct 05, 2012
Buy
Reiterated
3Ratings
0.00%
VPHM
Viropharma
Sep 13, 2013
Hold
Downgraded
3Ratings
0.00%
FPRX
Five Prime Therapeutics
Oct 14, 2013
Buy
Initiated
1Ratings
0.00%
NPSP
NPS Pharma
Feb 19, 2014
Buy
Assigned
2Ratings
0.00%
List of latest recommendations made by Brian Abrahams. Click to expand and see Brian Abrahams's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >